This year, the EMJ GOLD team were live on the ground at ESMO 2026 to learn the latest developments shaping the future of oncology
Interview by Cecilia Adamou
In this interview, hear from Pablo Panella, Senior Vice President, Head of Oncology for Europe and Canada, AstraZeneca, as he discusses the latest advances shaping the treatment landscape for patients with cancer.
Reflecting on progress across muscle-invasive bladder cancer, gastric cancer and lung cancer, Panella explores the impact of innovative therapies and emerging treatment approaches on patient outcomes.
The conversation covers a range of topics, including the potential of antibody-drug conjugates, novel treatment combinations, advances in precision medicine and targeted therapies, and the latest developments in lung cancer treatment.
Panella also shares his perspective on the challenges that continue to affect patient care, including access to innovative treatments, healthcare delivery and the complexities of accelerating reimbursement across diverse healthcare systems.
Guest bio
Pablo Panella, Senior Vice President, Head of Oncology for Europe and Canada, AstraZeneca
Pablo was appointed Senior Vice-President, Head of Oncology, for Europe and Canada in February 2026 and is responsible for driving commercial performance, strategic growth and patient access across one of AstraZeneca’s largest oncology regions. Prior to his current role, Pablo was Senior Vice-President for Global Respiratory & Immunology (R&I), responsible for AstraZeneca’s global R&I business and strategy for the Company’s current and future R&I portfolio of medicines. During his tenure at AstraZeneca, Pablo has held several senior manager positions including Senior Vice-President of the Western and Southern Europe Area (WESE), responsible for a cluster of 9 European countries and in charge of Europe and Canada’s Regional Commercial teams, Oncology Business Head in Spain, Commercial Director in the UK and Country President for AstraZeneca Italy. Pablo holds a BSc in Business from Austral University in Argentina, where he was born and has a dual citizenship (Argentinean/ Italian). He joined AstraZeneca in 2008 after completing his MBA in the Institute of Management Development (IMD) in Lausanne, Switzerland, in 2007.

